Search Results for “diabetes” – Page 4 – media

Type 2 diabetes patients who were physically active in the afternoon have greater reductions in blood sugar

Over 37 million Americans have diabetes, and 90-95% of that population are diagnosed with type 2 diabetes. Lifestyle interventions, such as a healthy diet and a regular physical activity program, are methods to manage diabetes. A new study from a collaboration of investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, and Joslin Diabetes Center, part of Beth Israel Lahey Health, uses data from the Look AHEAD (Action for Health in Diabetes) study, a randomized controlled trial that compared an intensive lifestyle intervention with diabetes support and education in patients diagnosed with type 2 diabetes and overweight or obesity to track the development of cardiovascular disease over time. In the current study, the research team assessed whether physical activity at certain times of day was associated with greater improvement in blood glucose control. Their findings suggest patients with type 2 diabetes who were ...
- Source: drugdu
- 124
- May 30, 2023
FDA approves Lexicon’s heart-failure drug after defeat in diabetes

Nicole DeFeudis Editor The FDA on Friday approved Lexicon’s heart failure drug sotagliflozin following a string of setbacks for the pharma company, including an FDA rejection in diabetes and the loss of a development deal with Sanofi. The dual SGLT1 and SGLT2 inhibitor will be marketed as Inpefa and is a once-daily tablet. It’s been approved to reduce the risk of cardiovascular death and heart failure-related hospitalization or urgent visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. The label spans the range of left ventricular ejection fraction, including preserved ejection fraction and reduced ejection fraction, as well as patients with or without diabetes, Lexicon said Friday. The company did not release Inpefa’s price but said it will be “comparable to existing branded heart failure medications.” Lexicon CEO Lonnel Coats expects the drug to hit the market by the end ...
- Source: drugdu
- 109
- May 30, 2023
Medtronic agrees to buy Korean insulin patch pump maker for $738m to boost diabetes business

Dive Brief: Medtronic agreed to buy EOFlow, a company based in South Korea that makes a tubeless, disposable insulin pump on a patch. The company will make a public tender offer to acquire all of EOFlow’s outstanding public shares for 971 billion South Korean won ($738 million). The purchase will allow Medtronic to compete with Insulet, which has gained market share with its tubeless insulin pumps, and Tandem Diabetes Care, which agreed last year to buy patch pump-maker AMF Medical. Dive Insight: Medtronic, with a warning letter recently lifted from its U.S. diabetes business, aims to bring new products to market. The company plans to integrate its new insulin dosing algorithm, which is used in the 780G pump, with EOFlow’s pump. “We’ve never lost faith in our technology,” Medtronic CEO Geoff Martha said on a Thursday earnings call, adding that “the patch segment is a good segment and we ...
- Source: https://www.medtechdive.com/news/medtronic-acquire-eoflow-patch-pump-insulin-MDT/651278/
- 114
- May 27, 2023
Common diabetes drug could be repurposed as a treatment for autoimmune disorders

Swansea University researchers have found that a drug commonly used to treat type 2 diabetes can potentially be used in the treatment of autoimmune disorders. Academics at the University’s Faculty of Medicine, Health and Life Science have found that the drug, canagliflozin (also known as Invokana), could be used to treat autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus as it targets T-cells, which form an essential component of the immune system. Canagliflozin is a drug that controls blood sugar levels in people with type 2 diabetes, however researchers have found an unexpected role for the drug involving the human immune system. Existing research has reported that targeting T-cell metabolism in autoimmunity can lead to therapeutic benefits. T-cells are a type of white blood cell that help the body fight infections and diseases, but in autoimmune diseases they have been observed to attack healthy tissues. The new study, ...
- Source: drugdu
- 134
- May 26, 2023
MyFitnessPal and Google Health Connect announce integration between two platforms to help people with diabetes

MyFitnessPal, the No. 1 global nutrition and fitness tracking app, and Google Health Connect today announced an integration between the two platforms at this year’s Google I/O developer conference. Individuals diagnosed with Type 1 and 2 diabetes who use select continuous glucose monitoring (CGM) tools integrated with Google’s Health Connect can now see their glucose data directly within the MyFitnessPal app. ”Our community will now have the critical capability to understand and visualize how the foods they eat affect their blood glucose levels throughout the day. Prior to this, someone could see spikes in their glucose, but not make the connection to what caused them. Our collaboration with Google builds on our innovation and commitment to bringing the latest technologies to consumers as they navigate their health and wellness journeys, particularly those with diet-related diseases.” Tricia Han, CEO, MyFitnessPal MyFitnessPal Android users with select glucose monitors now ...
- Source: drugdu
- 150
- May 15, 2023
New research reveals how coffee and tea can affect risk of early death for adults with diabetes

If you have type 2 diabetes, drinking more coffee, tea or plain water may lower your risk of dying prematurely from any cause by about 25%, a new study found. However, drinking more sugar-sweetened beverages raised the risk of heart disease by 25% and the risk of dying from a heart attack or another cardiovascular event by 29%, the study said. Research has shown cardiovascular disease is the most common cause of death for people with type 2 diabetes. “Certain beverages are absolutely more beneficial than others, depending on which type of beverage you’re comparing,” said study author Qi Sun, an associate professor of nutrition and epidemiology at the Harvard T.H. Chan School of Public Health in Boston. “Based on our study I would rank black coffee, unsweetened tea and plain water higher than low-fat milk, fruit juice or artificially sweetened beverages,” he said. “Sugar-sweetened beverages like ...
- Source: drugdu
- 128
- April 24, 2023
Refined carbs and red meat driving global rise in type 2 diabetes, study says

Gobbling up too many refined wheat and rice products, along with eating too few whole grains, is fueling the growth of new cases of type 2 diabetes worldwide, according to a new study that models data through 2018. “Our study suggests poor carbohydrate quality is a leading driver of diet-attributable type 2 diabetes globally,” says senior author Dr. Dariush Mozaffarian, a professor of nutrition at Tufts University and professor of medicine at Tufts School of Medicine in Boston, in a statement. Another key factor: People are eating far too much red and processed meats, such as bacon, sausage, salami and the like, the study said. Those three factors — eating too few whole grains and too many processed grains and meats — were the primary drivers of over 14 million new cases of type 2 diabetes in 2018, according to the study, which was published Monday in the ...
- Source: drugdu
- 123
- April 18, 2023
Complications, pathophysiology, and treatment of type 2 diabetes differ by sex

In a recent review published in the journal Diabetologia, researchers in Austria discussed the sex-based differences in the risk factors, diagnosis, and therapeutic approaches for type 2 diabetes and associated complications to improve awareness about and management options for all diabetes type 2 patients. Background Studies show that patterns associated with type 2 diabetes vary according to sex, with the prevalence of the disease being higher among the young to middle-aged male population but the increase in postprandial glucose levels being higher among women and increasing with age. Furthermore, the varying clinical outcomes based on sex depend on the influence of hormonal and genetic factors on the diagnoses, therapeutic response, clinical outcomes, and pathophysiology. Therefore, because of the varying levels of sex hormones, the risk of type 2 diabetes and other cardiometabolic diseases also varies significantly for women. Additionally, substantial sex-based differences in lifestyles, behaviors, and approaches ...
- Source: drugdu
- 151
- March 28, 2023
Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients

Bayer’s first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) Kerendia has received approval in the US to slow chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D). The US Food and Drug Administration (FDA) has cleared Kerendia (finerenone) to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction (MI) and hospitalisation for heart failure in adult patients with CKD associated with T2D. The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study, which showed Kerendia significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care. The drug also lowered the risk of a composite of time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke or heart failure hospitalisation, thereby by also meeting secondary targets. “Kerendia is the first and only nonsteroidal mineralocorticoid receptor ...
- Source: drugdu
- 1,036
- August 26, 2021
diabetes
China’s Import and Export Market Report of Diabetes Drugs

Diabetes is one of the most common chronic diseases and is mainly classified into type 1 diabetes, type 2 diabetes, gestational diabetes and others. Worldwide, 90% of diabetic patients suffer from type 2 diabetes, which greatly promotes the development of the diabetes drug market.
- Source: Ddu
- 49,927
- August 25, 2021
Ddu College Diabetes Drugs

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.